...giants such as Procter & Gamble (PG), Costco Wholesale (COST) and Kraft Foods (KFT), and health care firms such as Johnson & Johnson (JNJ) and Novartis (NVS), posted decent financial figures in recent quarters. A few companies, such as McDonald's, have outperformed...

...there are opportunities galore for forward-thinking companies with enough guts to make such a bold acquisition. He praised Johnson & Johnson, a stock which he owns for his charitable trust, Action Alerts PLUS, for being one of those companies. With the markets...

...for the losing bidder, break fees can sometimes help boost their earnings. This was the case for Johnson & Johnson, which received a $705m payment from Guidant in 2005 after the healthcare group ditched J&J in favour of a higher offer from Boston Scientific...

...have a lot of financial flexibility coming into a downturn like we're in, and in many cases, they'll gain market share. Johnson & Johnson just announced the acquisition of a cosmetic company called Mentor. Essentially, companies like these are going into the...

...playing on an outdoor digital billboard in Times Square. (Walgreens unveiled the massive display last month; Kraft, Johnson & Johnson and several other packaged goods companies have all bought ad space.) Laurie Guzzinati, associate director of corporate affairs...

...of companies that have exceptional track records of delivering the ROE goods include IBM (NYSE: IBM) and Johnson & Johnson (NYSE: JNJ). Each posted juicy ROE figures this year, easily trumping their respective industry averages that year. Both firms have continued...

...opportunities abound. Cohen recommended strong blue-chip companies with good balance sheets and high dividend yields, like Johnson & Johnson. None wanted to predict how long the stock market’s record volatility would continue, but as Legg’s star fund manager,...

...10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events...

...has been commenced on behalf of shareholders of Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI) in connection with the offer by Johnson & Johnson to acquire all of the outstanding shares of OMRI. The case is pending in The Supreme Court of the State of New York,...

...drug for the same indication, with results expected before year-end. A FDA decision is also possible before year-end for Johnson & Johnson (JNJ) and Medarex (MEDX) for a biological agent, Stelara (ustekinumab), in the treatment of psoriasis – with a FDA panel...